BioSpace News Archive

Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, is proud to announce that Dr. Dan Siman-Tov, Ph.D., MBA, Senior Director of R&D, Diagnostics, will be presenting at the Advanced Lateral Flow Conference 2024.

Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the independent Data Monitoring Committee (DMC) recommended continuation of the pivotal Phase 3 trial (PRESERVE 2), evaluating trilaciclib in combination with gemcitabine and carboplatin for the first line treatment of metastatic triple negative breast cancer (mTNBC), to the final analysis.

Sana Biotechnology, Inc. announced that it has closed its underwritten upsized public offering of 21,772,728 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 4,500,000 additional shares of its common stock, at a price to the public of $5.50 per share.

Johnson & Johnson (NYSE: JNJ) will participate in the Leerink Global Biopharma Conference on Tuesday, March 12th, at the Fontainebleau Miami Beach, FL.

Connect Biopharma Holdings Limited announced the appointment of James Zuie-chin Huang, M.B.A., to its Board of Directors effective immediately.

Exactech will showcase a full lineup of innovative implants and enabling technologies this week at the American Academy of Orthopaedic Surgeons (AAOS) 2024 Annual Meeting, Booth 951, in San Francisco, Ca.

BioHarvest Sciences Inc. a pioneer in Botanical Synthesis technology that grows Phyto-active compositions without growing the plant, announces its upcoming participation and sponsorship of the 2024 BIO CEO & Investor Conference, which will take place in New York City from February 26-27, 2024.

RapidAI, the global leader in developing Artificial Intelligence (AI) and clinical workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, today announced the publication of the TIMELESS trial in the New England Journal of Medicine (NEJM).

Key regulatory milestone advances company’s mission to perfect cancer diagnosis